Global AI Spotlight: DataGlobal Hub Assembles Hundreds of Industry Leaders for GDAI 2025, The Largest Global Virtual AI & Data Conference
PHOENIX, June 20, 2025 (GLOBE NEWSWIRE) -- DataGlobal Hub, a fast-growing global…
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial…
Kia Wins Gold at PR Awards AsiaPacific 2025 for PR Communication Promoting Global Awareness of Ocean Plastic Cleanup
Kia Global PR Group wins Gold award in Environmental category at PR…
Cyber Media Tour with AITO Concludes: Reaffirming Commitment to Global New Luxury Mobility
CHONGQING, China, June 12, 2025 /PRNewswire/ -- From June 10 to 12, …
Asia Tech x Singapore 2025 Recap
SINGAPORE, June 10, 2025 /PRNewswire/ -- At the recent ATxSummit, the apex event…
NYSE Content Advisory: NYSE, Money20/20, FINTECH.TV, and Cheddar create “Taking Stock”
NEW YORK, June 3, 2025 /PRNewswire/ -- The New York Stock Exchange…
![Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]](https://i0.wp.com/ml-eu.globenewswire.com/media/NjEzMmQ4NzAtZTBkMS00ZDhhLTkyYjgtOGM3YzY1ZWM5M2U5LTEwMTQyODItMjAyNS0wNi0wMi1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]")
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA…